Celcuity (CELC) said Monday it was granted a new patent covering the clinical dosing regimen for gedatolisib, its drug candidate for estrogen receptor-positive, HER2-negative breast cancer.
The new issuance brought to 13 the gedatolisib-related patents in the US and extended exclusivity in the US into 2042, according to the company.
Celcuity said it expects to report topline data for the PIK3CA wild-type cohort of its phase 3 trial of gedatolisib in Q3, and for the PIK3CA mutant cohort in Q4.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。